Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells

Cytokine

Volumn 60, Issue 2, 2012, Pages 514-521

  Schmieder, Annett ^a   Multhoff, Gabriele ^b,c   Radons, Jürgen ^d  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d Multimmune GmbH   (Germany)

Author keywords

Colo357; Cytokines; IL 33; NF B; ST2 ST2L

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 3; INTERLEUKIN 33; INTERLEUKIN 6; INTERLEUKIN 8; MEMBRANE PROTEIN; MESSENGER RNA; PROTEIN ST2; UNCLASSIFIED DRUG;

ARTICLE; CANCER INVASION; CARCINOGENESIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LIGAND BINDING; NUCLEOTIDE SEQUENCE; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; TUMOR GROWTH; UPREGULATION;

ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1; INTERLEUKINS; MICE; NEOPLASM METASTASIS; NF-KAPPA B; PANCREATIC NEOPLASMS; RECEPTORS, CELL SURFACE; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84866755060     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.06.286     Document Type: Article

References (63)

1. Multhoff G., Molls M., Radons J. Chronic inflammation in cancer development. Front Immunol 2012, 2:98. 10.3389/fimmu.2011.0009.
2. Angst E., Reber H.A., Hines O.J., Eibl G. Mononuclear cell-derived interleukin-1 beta confers chemoresistance in pancreatic cancer cells by upregulation of cyclooxygenase-2. Surgery 2008, 144:57-65.
3. McKay C.J., Glen P., McMillan D.C. Chronic inflammation and pancreatic cancer. Best Pract Res Clin Gastroenterol 2008, 22:65-73.
4. Bachem M.G., Schunemann M., Ramadani M., Siech M., Beger H., Buck A., et al. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 2005, 128:907-921.
5. Masamune A., Watanabe T., Kikuta K., Shimosegawa T. Roles of pancreatic stellate cells in pancreatic inflammation and fibrosis. Clin Gastroenterol Hepatol 2009, 7:S48-S54.
6. Shimizu K. Mechanisms of pancreatic fibrosis and applications to the treatment of chronic pancreatitis. J Gastroenterol 2008, 43:823-832.
7. Vonlaufen A., Phillips P.A., Xu Z., Goldstein D., Pirola R.C., Wilson J.S., et al. Pancreatic stellate cells and pancreatic cancer cells: an unholy alliance. Cancer Res 2008, 68:7707-7710.
8. Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T.K., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23:479-490.
9. Palmer G., Lipsky B.P., Smithgall M.D., Meininger D., Siu S., Talabot-Ayer D., et al. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine 2008, 42:358-364.
10. Hayakawa H., Hayakawa M., Kume A., Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 2007, 282:26369-26380.
11. Milovanovic M., Volarevic V., Radosavljevic G., Jovanovic I., Pejnovic N., Arsenijevic N., et al. IL-33/ST2 axis in inflammation and immunopathology. Immunol Res 2012, 9:90.
12. Miller A.M. Role of IL-33 in inflammation and disease. J Inflamm (Lond) 2011, 8:22.
13. Haraldsen G., Balogh J., Pollheimer J., Sponheim J., Kuchler A.M. Interleukin-33 - cytokine of dual function or novel alarmin?. Trends Immunol 2009, 30:227-233.
14. Karin M. Nuclear factor-κB in cancer development and progression. Nature 2006, 441:431-436.
15. Fahy B.N., Schlieman M.G., Virudachalam S., Bold R.J. Inhibition of AKT abrogates chemotherapy-induced NF-κB survival mechanisms: implications for therapy in pancreatic cancer. J Am Coll Surg 2004, 198:591-599.
16. Singh S., Khar A. Biological effects of curcumin and its role in cancer chemoprevention and therapy. Anticancer Agents Med Chem 2006, 6:259-270.
17. Carriere V., Roussel L., Ortega N., Lacorre D.A., Americh L., Aguilar L., et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA 2007, 104:282-287.
18. Roussel L., Erard M., Cayrol C., Girard J.P. Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep 2008, 9:1006-1012.
19. Moulin D., Donze O., Talabot-Ayer D., Mezin F., Palmer G., Gabay C. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 2007, 40:216-225.
20. Smithgall M.D., Comeau M.R., Yoon B.R., Kaufman D., Armitage R., Smith D.E. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol 2008, 20:1019-1030.
21. Sanada S., Hakuno D., Higgins L.J., Schreiter E.R., McKenzie A.N., Lee R.T. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007, 117:1538-1549.
22. Miller A.M., Xu D., Asquith D.L., Denby L., Li Y., Sattar N., et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008, 205:339-346.
23. McLaren J.E., Michael D.R., Salter R.C., Ashlin T.G., Calder C.J., Miller A.M., et al. IL-33 reduces macrophage foam cell formation. J Immunol 2010, 185:1222-1229.
24. Davenport P., Tipping P.G. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 2003, 163:1117-1125.
25. Gupta S., Pablo A.M., Jiang X., Wang N., Tall A.R., Schindler C. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 1997, 99:2752-2761.
26. Masamune A., Watanabe T., Kikuta K., Satoh K., Kanno A., Shimosegawa T. Nuclear expression of interleukin-33 in pancreatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2010, 299:G821-G832.
27. Nishida A., Andoh A., Imaeda H., Inatomi O., Shiomi H., Fujiyama Y. Expression of interleukin 1-like cytokine interleukin 33 and its receptor complex (ST2L and IL1RAcP) in human pancreatic myofibroblasts. Gut 2010, 59:531-541.
28. Morgan R.T., Woods L.K., Moore G.E., Quinn L.A., McGavran L., Gordon S.G. Human cell line (COLO 357) of metastatic pancreatic adenocarcinoma. Int J Cancer 1980, 25:591-598.
29. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
30. Radons J., Gabler S., Wesche H., Korherr C., Hofmeister R., Falk W. Identification of essential regions in the cytoplasmic tail of interleukin-1 receptor accessory protein critical for interleukin-1 signaling. J Biol Chem 2002, 277:16456-16463.
31. Hoffmann J., Junker H., Schmieder A., Venz S., Brandt R., Multhoff G., et al. EGCG downregulates IL-1RI expression and suppresses IL-1-induced tumorigenic factors in human pancreatic adenocarcinoma cells. Biochem Pharmacol 2011, 82:1153-1162.
32. Liu X.H., Kirschenbaum A., Yao S., Levine A.C. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-κB (RANK) ligand/RANK system. Endocrinology 2005, 146:1991-1998.
33. Wu T. Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma. Biochim Biophys Acta 2005, 1755:135-150.
34. Stangl S., Wortmann A., Guertler U., Multhoff G. Control of metastasized pancreatic carcinomas in SCID/beige mice with human IL-2/TKD-activated NK cells. J Immunol 2006, 176:6270-6276.
35. Gastpar R., Gross C., Rossbacher L., Ellwart J., Riegger J., Multhoff G. The cell surface-localized heat shock protein 70 epitope TKD induces migration and cytolytic activity selectively in human NK cells. J Immunol 2004, 172:972-980.
36. Multhoff G., Botzler C., Wiesnet M., Müller E., Meier T., Wilmanns W., et al. A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells. Int J Cancer 1995, 61:272-279.
37. Härdtner C., Multhoff G., Falk W., Radons J. (-)-Epigallocatechin-3-gallate, a green tea-derived catechin, synergizes with celecoxib to inhibit IL-1-induced tumorigenic mediators by human pancreatic adenocarcinoma cells Colo357. Eur J Pharmacol 2012, 684:36-43.
38. Hönicke A.S., Ender S.A., Radons J. Combined administration of EGCG and IL-1 receptor antagonist efficiently downregulates IL-1-induced tumorigenic factors in U-2 OS human osteosarcoma cells. Int J Oncol 2012, 41:753-758.
39. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Müller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003, 374:1-20.
40. Rose-John S., Schooltink H. Cytokines are a therapeutic target for the prevention of inflammation-induced cancers. Recent Results Cancer Res 2007, 174:57-66.
41. Weiss T.W., Simak R., Kaun C., Rega G., Pflüger H., Maurer G., et al. Oncostatin M and IL-6 induce u-PA and VEGF in prostate cancer cells and correlate in vivo. Anticancer Res 2011, 31:3273-3278.
42. Waugh D.J., Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008, 14:6735-6741.
43. Takamori H., Oades Z.G., Hoch O.C., Burger M., Schraufstatter I.U. Autocrine growth effect of IL-8 and GROα on a human pancreatic cancer cell line, Capan-1. Pancreas 2000, 21:52-56.
44. Yao C., Lin Y., Chua M.S., Ye C.S., Bi J., Li W., et al. Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells. Int J Cancer 2007, 121:1949-1957.
45. Koch A.E., Polverini P.J., Kunkel S.L., Harlow L.A., DiPietro L.A., Elner V.M., et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992, 258:1798-1801.
46. Li A., Dubey S., Varney M.L., Dave B.J., Singh R.K. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003, 170:3369-3376.
47. De Larco J.E., Wuertz B.R., Furcht L.T. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res 2004, 10:4895-4900.
48. Shi Q., Abbruzzese J.L., Huang S., Fidler I.J., Xiong Q., Xie K. Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res 1999, 5:3711-3721.
49. Bendre M.S., Margulies A.G., Walser B., Akel N.S., Bhattacharrya S., Skinner R.A., et al. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-κB ligand pathway. Cancer Res 2005, 65:11001-11009.
50. Wang Y., Qu Y., Niu X.L., Sun W.J., Zhang X.L., Li L.Z. Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cytokine 2011, 56:365-375.
51. Martinez M.L., Lucas P., Navarro G., Checa A.I., Franco R., Martinez A., et al. Dynamic regulation of CXCR1 and CXCR2 homo- and heterodimers. J Immunol 2009, 183:7337-7346.
52. Doroshenko T., Chaly Y., Savitskiy V., Maslakova O., Portyanko A., Gorudko I., et al. Phagocytosing neutrophils down-regulate the expression of chemokine receptors CXCR1 and CXCR2. Blood 2002, 100:2668-2671.
53. Maheshwari A., Voitenok N.N., Akalovich S., Shaik S.S., Randolph D.A., Sims B., et al. Developmental changes in circulating IL-8/CXCL8 isoforms in neonates. Cytokine 2009, 46:12-16.
54. Michiel D.F., Oppenheim J.J. Cytokines as positive and negative regulators of tumor promotion and progression. Semin Cancer Biol 1992, 3:3-15.
55. Tahara H., Lotze M.T. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene ther 1995, 2:96-106.
56. Zaharoff D.A., Hance K.W., Rogers C.J., Schlom J., Greiner J.W. Intratumoral immunotherapy of established solid tumors with chitosan/IL-12. J Immunother 2010, 33:697-705.
57. Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 1998, 70:83-243.
58. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995, 13:251-276.
59. Meephansan J., Komine M., Tsuda H., Tominaga S., Ohtsuki M. Ultraviolet B irradiation induces the expression of IL-33 mRNA and protein in normal human epidermal keratinocytes. J Dermatol Sci 2011, 65:72-74.
60. Jovanovic I., Radosavljevic G., Mitrovic M., Juranic V.L., McKenzie A.N., Arsenijevic N., et al. ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma. Eur J Immunol 2011, 41:1902-1912.
61. Choi Y.S., Choi H.J., Min J.K., Pyun B.J., Maeng Y.S., Park H., et al. Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood 2009, 114:3117-3126.
62. Sun P., Ben Q., Tu S., Dong W., Qi X., Wu Y. Serum interleukin-33 levels in patients with gastric cancer. Dig Dis Sci 2011, 56:3596-3601.
63. Byrne S.N., Beaugie C., O'Sullivan C., Leighton S., Halliday G.M. The immune-modulating cytokine and endogenous alarmin interleukin-33 is upregulated in skin exposed to inflammatory UVB radiation. Am J Pathol 2011, 179:211-222.